MSB Trading - 2019, page-2200

Thanks for the uplifting and honest reply Otherperspective.

In my heart I was hoping for an approval for this indication with a condition of a confirmatory trial after marketing.

This would have allowed manufacturing to start and a slow rollout of product to begin.

This could have helped set the stage for mass rollout for heart therapy or back pain.

Reality is the status quo of big pharma is offering no shortcuts.

GVHD could have been approved by now. We should have qualified for the juvenile voucher worth a few hundred million dollars.

I know we all have been waiting patiently for the regulatory bodies but at some point we better look at getting vocal and speaking out.

I was invested in Dendreon and man that was a grass roots movement that got the attention of the FDA.

Good luck my fellow visionaries and revolutionaries